Mind Medicine (MindMed) Inc. announced that in collaboration with University Hospital Basel's Liechti Laboratory, it has discovered and filed a patent application in the United States (preserving all worldwide rights) for a neutralizer technology intended to shorten and stop the effects of an LSD trip during a therapy session.
This discovery, when further developed, may act as the 'off-switch' to an LSD trip.
MindMed is the leading psychedelic pharmaceutical company and the Liechti Laboratory is the leading research center focused on the pharmacology of psychedelic substances.
The invention may help reduce the acute effects of a psychedelic drug and help shorten the hallucinogenic effects when required by a patient or medical professional.
MindMed CEO Rob Barrow at Web Summit 2021: Therapy 2.0 - The next step in mental health
February 1, 2022